Bosutinib

Drug Profile

Bosutinib

Alternative Names: Bosulif; PF-05208763; PF-5208763; SKI-606

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Avillion; Massachusetts General Hospital; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class Aniline compounds; Antineoplastics; Nitriles; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Glioblastoma
  • Phase I/II Acute lymphoblastic leukaemia
  • Discontinued Autosomal dominant polycystic kidney disease; Breast cancer; Solid tumours

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse event data from a pooled analysis in Chronic myeloid leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 15 Mar 2016 Biomarkers information updated
  • 08 Sep 2015 Avillion completes enrolment in its phase III BFORE trial in Chronic myeloid leukaemia (First line therapy) in USA, Australia, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, South Korea, Mexico, Netherlands, Norway, Poland, Singapore, Slovakia, South Africa, Spain, Sweden, Taiwan, Thailand, Ukraine and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top